Break of consolidation IMU is trying to push through resistance.
Consolidating for a number of weeks.
Had a push today on above average volume.
Needs to get above 0.12 and have a daily close.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.021 AUD
−149.68 M AUD
0.00 AUD
6.29 B
About IMUGENE LIMITED
Sector
Industry
CEO
Leslie Chong
Website
Headquarters
Sydney
Founded
1986
ISIN
AU000000IMU9
FIGI
BBG000BZ3TD8
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Imugene Limited (ASX: IMU) Director's Increase Stake"Imugene Limited (ASX: IMU) Director's Stake Update: On 12th Jan '24, a director affirmed their commitment by acquiring 1M RSUs at no cost, signaling bullish sentiment. Pre-acquisition, the director held 600K options and 20.73M shares, maintaining these post-acquisition. No options or shares were so
Finer Market Points: ASX Top 10 Momentum Stocks: 30 Nov 2023ASX:SHN ASX:TCG ASX:TG6 NYSE:STK SET:PLT ASX:VMM ASX:EQN ASX:FL1 ASX:IMU ASX:4DX
Momentum-leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on
Box and Squeeze Strategy - Darvas InspiredDescription
The "Combined Box and Squeeze Strategy" is a comprehensive trading script developed for the TradingView platform. It merges two distinct analytical approaches: "The Box Percent Strat" and "Squeeze Box ," offering traders a multifaceted tool for market analysis.
Key Features
Box Perce
Trend Following and SMA CrossDescription:
This innovative trading strategy is a synergistic blend of two proven approaches: Trend Following and Simple Moving Average (SMA) Crossover. It harnesses the strengths of each to offer a more robust trading system designed for a variety of markets.
Key Features:
Trend Following Compo
Short as long as 0.459 is resistanceAlternative scenario: the upside breakout of 0.459 would call for 0.509 and 0.539.
My pivot point is at 0.459.
My preference: the downside prevails as long as 0.459 is resistance.
Comment:
The RSI is below its neutrality area at 50.
The MACD is negative and below its signal line.
The configu
IMU @ 18 NOV 2021Text me if you have any questions/comments for me.
-----
IMU
- Previous analysis was done on 4 Oct (red arrow) – suggested waiting for a successful rebound around 47.5 cents before plotting entry
- Since then, the stock has created a new high, retraced, and looks to be rebounding off the short-te
IMU @ 4 OCT 2021Text me if you have any questions/comments for me.
-----
IMU
- First time doing a written analysis on IMU
- Stock is currently trading at previous strong resistance (created in 2007)
- A good rebound from here would form a strong support at current levels
- A successful rebound looks to be at 0.47
$IMU measured move to determine exit priceA measured move calculation that is used to determine the exit price from a break out.
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMU is 0.036 AUD — it hasn't changed in the past 24 hours. Watch IMUGENE LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange IMUGENE LIMITED stocks are traded under the ticker IMU.
IMU stock has fallen by −5.26% compared to the previous week, the month change is a −5.26% fall, over the last year IMUGENE LIMITED has showed a −65.71% decrease.
IMU stock is 2.78% volatile and has beta coefficient of 0.46. Track IMUGENE LIMITED stock price on the chart and check out the list of the most volatile stocks — is IMUGENE LIMITED there?
Today IMUGENE LIMITED has the market capitalization of 267.78 M, it has decreased by −5.26% over the last week.
Yes, you can track IMUGENE LIMITED financials in yearly and quarterly reports right on TradingView.
IMUGENE LIMITED is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
IMU earnings for the last half-year are −0.01 AUD per share, whereas the estimation was −0.01 AUD, resulting in a 0.00% surprise. The estimated earnings for the next half-year are −0.01 AUD per share. See more details about IMUGENE LIMITED earnings.
IMUGENE LIMITED revenue for the last half-year amounts to −1.55 M AUD, despite the estimated figure of 0.00 AUD. In the next half-year revenue is expected to reach 7.00 M AUD.
IMU net income for the last half-year is −80.97 M AUD, while the previous report showed −68.71 M AUD of net income which accounts for −17.83% change. Track more IMUGENE LIMITED financial stats to get the full picture.
No, IMU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMUGENE LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMUGENE LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMUGENE LIMITED stock shows the sell signal. See more of IMUGENE LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.